AMRX.NASDAQAmneal Pharmaceuticals, INC

DEF 14A: Amneal Pharmaceuticals Seeks Stockholder Approval for Executive Pay and Auditor Appointment at 2024 Annual Meeting

Sentiment:

Proxy Statement

📋All filings for Amneal Pharmaceuticals, INC
🔒Login to Follow

Amneal Pharmaceuticals is holding its 2024 Annual Meeting of Stockholders on May 2, 2024, to vote on director elections, executive compensation, and the ratification of its independent auditor.

Summary

  • Amneal Pharmaceuticals is holding its 2024 Annual Meeting of Stockholders on May 2, 2024, to vote on several key proposals.
  • Stockholders will elect 11 directors, provide an advisory vote on executive compensation, and ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2024.
  • The proxy statement details the company's performance in 2023, including revenue growth of 8% and adjusted EBITDA growth of 8.6%.
  • It also outlines the compensation structure for named executive officers (NEOs) and provides information on corporate governance practices.
  • The company emphasizes its commitment to providing affordable medicines and creating value for stakeholders.
  • Amneal's corporate structure was reorganized in 2023 to simplify operations and is expected to drive significant cash savings.
  • The Board recommends voting 'FOR' all director nominees, the advisory vote on executive compensation, and the ratification of Ernst & Young LLP.
  • The company's executive compensation program is designed to attract, motivate, and retain talented executives while aligning their interests with those of stockholders.
  • A significant portion of executive compensation is tied to the company's annual and long-term performance.
  • The company's financial performance in 2023 was strong, with revenue reaching $2,394 million and adjusted EBITDA at $558 million.
  • Amneal successfully launched three biosimilars and expanded its international presence.
  • The company's net leverage decreased from 7.4x in 2019 to 4.8x in 2023, with a target of below 4.0x in 2025.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, highlighting growth and strategic initiatives. However, it also acknowledges risks and challenges inherent in the pharmaceutical industry, resulting in a moderately positive sentiment score.

Positives

  • The company achieved strong financial performance in 2023, with revenue and adjusted EBITDA growth.
  • Amneal successfully launched new products and expanded its international presence.
  • The company refinanced its debt and reorganized its corporate structure to improve financial stability and efficiency.
  • The company has a strong commitment to corporate responsibility and ESG principles.
  • The company's executive compensation program is designed to align the interests of executives with those of stockholders.
  • The company has a majority of independent directors on its Board, and each Board committee is comprised entirely of independent directors.

Negatives

  • The company reported a net loss of $(84) million in 2023.
  • The company's stock price performance has been volatile.
  • The company is subject to risks related to the pharmaceutical industry, including competition, regulatory changes, and litigation.

Risks

  • The company faces competition from brand and generic drug product companies.
  • The company's revenues are derived from a limited number of products and customers.
  • The company is dependent on third-party suppliers and distributors.
  • The company is subject to legal, regulatory, and legislative efforts by brand competitors to deter competition from generic alternatives.
  • The company is dependent on information technology systems and infrastructure and the potential for cybersecurity incidents.
  • The company has a substantial amount of indebtedness and its ability to generate sufficient cash to service its indebtedness in the future.
  • The company's potential expansion into additional international markets subjects it to increased regulatory, economic, social, and political uncertainties.
  • The company's obligations under a tax receivable agreement may be significant.
  • The high concentration of ownership of the company's class A common stock and the fact that it is controlled by the Amneal Group.

Future Outlook

The company aims to achieve a net leverage below 4.0x in 2025 and continues to focus on growth and diversification across its business segments.

Management Comments

  • 2023 was a robust year of growth, outstanding execution, and further diversification of our business as we expanded in new high growth areas.
  • We are a diversified and growing pharmaceutical company across Retail, Injectables, Biosimilars, Specialty, Distribution and International.
  • Our company's mission centers on improving access to affordable, high-quality, and innovative medicines across these areas.
  • We are extremely proud of our colleagues, and the passion they bring in delivering value as We make healthy possible.

Industry Context

Amneal operates in the global, affordable medicines sector, which is characterized by complex and challenging times. The company's strategy focuses on providing high-quality, affordable medicines and creating value for all stakeholders in a rapidly evolving healthcare environment.

Comparison to Industry Standards

  • The document compares Amneal's TSR to the Russell 2000 Index, Nasdaq Composite Total Return Index, and Dow Jones U.S. Select Pharmaceuticals Index.
  • The Compensation Committee uses a peer group of publicly traded companies, including Alkermes plc, Mallinckrodt plc, and Teva Pharmaceutical Industries Limited, to evaluate executive compensation.
  • At the time of the Compensation Committees September 2022 peer group review, Amneal approximated the 65th, 25th and 40th percentiles for revenue, market capitalization and enterprise value, respectively, relative to the 2023 compensation peer group.

Related Party Transactions

  • The company has related party transactions with entities in which certain directors and executive officers have a financial interest.
  • These transactions are reviewed and approved by the Conflicts Committee of the Board of Directors.
  • Related party transactions include lease agreements, service agreements, and license agreements.

Stakeholder Impact

  • The company's performance and strategic initiatives impact shareholders, employees, customers, and suppliers.
  • The company's commitment to providing affordable medicines benefits patients and the healthcare system.
  • The company's corporate responsibility and ESG efforts contribute to building healthy communities and a healthy planet.

Next Steps

  • Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
  • The company will continue to execute its strategy to provide affordable medicines and create value for stakeholders.
  • The company will continue to monitor and manage risks related to its business and industry.

Key Dates

DateDescription
2002Amneal Pharmaceuticals, Inc. founded.
2018Amneal LLC completed the acquisition of Impax Laboratories, Inc.
May 4, 2018Members of the Amneal Group entered into definitive purchase agreements (the PIPE Purchase Agreement) that provided for a private placement of certain shares of Class A common stock and Class B-1 common stock (the PIPE Investment) with select institutional investors (the PIPE Investors).
August 2019Stockholders agreement with the Amneal Group was amended and restated.
August 2020Amneal and Kashiv entered into a product development agreement for the development and commercialization of two generic peptide products, Ganirelix Acetate and Cetrorelix Acetate.
March 11, 2020Anastasios Konidaris Employment Agreement, dated March 11, 2020, by and among Amneal, the Company and Mr. Konidaris (the Konidaris Employment Agreement).
July 29, 2020Nikita Shah Employment Agreement, dated July 29, 2020, by and among Amneal, the Company and Ms. Shah (the Shah Employment Agreement).
August 12, 2021The Company entered into an active pharmaceutical ingredient (API) co-development agreement with a subsidiary of Fosun.
December 10, 2021Mr. Patel has pledged to Credit Suisse AG 21,269,420 shares of Class A common stock to secure the obligations of those certain borrowers to the Promissory Note and Collateral Agreement dated December 10, 2021 (as modified from time to time).
February 9, 2022The acquisition of the baclofen franchise from certain entities affiliated with Saol International Limited, which closed on February 9, 2022.
May 27, 2022The FDA approved the biologic license application, associated with the amended Kashiv License Agreement, for Pegfilgrastim-pbbk.
July 2022The Company and Kashiv amended the Kashiv License Agreement to, among other things, (i) eliminate milestones related to the manufacturing and delivery of the Kashiv products, (ii) revise the net sales milestones to provide for future milestone payments by the Company to Kashiv of up to $37.5 million for the achievement of cumulative combined net sales goals for both products, and (iii) adjust the supply price of product that Kashiv manufactures and supplies to the Company, which will lower the cost per unit of both products.
December 2022Amneal and Kashiv entered into a development supply agreement specific to four generic product candidates.
February 21, 2023The Company entered into Modification No. 2 to the Boyer Employment Agreement, effective as of March 1, 2023 (the Effective Date).
February 21, 2023The Company entered into Modification No. 2 to the Konidaris Employment Agreement, effective as of March 1, 2023 (the Effective Date).
February 21, 2023The Company entered into Modification No. 1 to the Shah Employment Agreement, effective as of March 1, 2023 (the Effective Date).
May 12, 2023The Company and Kashiv amended the Kashiv License Agreement to provide for, among other things, (i) Kashiv to have the right to develop either or both an auto-injector delivery system or an on-body injector for the biosimilar PEG-filgrastim, and (ii) the Company to have a right of first negotiation to launch and commercialize either or both of such products.
August 11, 2023The Company and Fosun amended the license and supply agreement to, among other things, (i) increase the products subject to the agreement from eight to ten, (ii) eliminate the first commercial sales milestone of $0.3 million for each product and (iii) decrease the profit share percentage applicable to all products.
November 7, 2023The Company implemented a plan pursuant to which the Company and Amneal LLC reorganized and we simplified our corporate structure by eliminating our umbrella partnership-C-corporation structure and converting to a more traditional structure whereby all stockholders hold their voting and economic interests directly through the public company (the Reorganization).
December 27, 2023Shortly after we effected the Reorganization, at market open on December 27, 2023, we transferred the listing of our Class A common stock to the Nasdaq Stock Market LLC (Nasdaq).
March 11, 2024Record date for the 2024 Annual Meeting of Stockholders.
May 2, 2024Amneal Pharmaceuticals, Inc. 2024 Annual Meeting of Stockholders.
November 22, 2024Deadline for stockholder proposals for inclusion in the 2025 proxy statement.
January 2, 2025Earliest date for submitting director nominations and other proposals for the 2025 annual meeting (outside of proxy statement).
February 1, 2025Latest date for submitting director nominations and other proposals for the 2025 annual meeting (outside of proxy statement).
March 3, 2025Deadline for stockholders to provide notice of intent to solicit proxies in support of director nominees other than the Company's nominees.
May 2025Expected date of the 2025 Annual Meeting of Stockholders.

Keywords

executive compensation, annual meeting, proxy statement, pharmaceuticals, corporate governance, financial performance, Amneal, directors, EBITDA, biosimilars, generics

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.